Member Info for Saint68

No problem 👍

From Grok :

In 2024, Hemogenyx announced a new and improved version of CDX, developed using Lonza’s bYlok bispecific pairing technology. This version aimed to enhance the original candidate’s properties for better performance in relapsed/refractory AML. 

Lilly’s IP affects this improved version in the following ways:

• Enabling access and freedom to operate: The licensed Lilly IP covers aspects of the original CDX (sequences, methods, or related know-how from the collaboration). Without the license, developing or commercializing derivatives or improvements built on that foundation could risk infringement claims. The exclusive license provides Hemogenyx with the legal right to build upon and improve the asset. 

• Limited scope to Lilly’s contributions: Lilly’s IP is tied to what was developed/validated during the collaboration, not necessarily every aspect of the new improved version. Hemogenyx has its own patent portfolio for CDX, including:

• A core U.S. patent (US 11,021,536 B2) on CDX bi-specific antibodies.

• Additional patents/applications on composition of matter for novel sequences (some stemming from the Lilly collaboration, e.g., WO/2023/023489), methods of use, and conditioning approaches.

• Grants in China and further U.S. protections. 
The improved version likely incorporates Hemogenyx’s own innovations (e.g., via bYlok technology) and new sequences, strengthening Hemogenyx’s independent IP position.

• Financial and contractual obligations: The license imposes ongoing payments (milestones) and sub-licensing sharing, which apply to exploitation of the licensed IP—even in improved forms derived from the original program. This creates a modest royalty-like or milestone burden but is described by Hemogenyx as opening a “low-cost path” to clinical proof-of-concept compared to alternatives. 

• No blocking effect reported: Public announcements and investor materials frame the Lilly license as facilitative rather than restrictive. Hemogenyx emphasizes its “strong Intellectual Property position and know-how” overall, with the Lilly license providing validation and cleared rights from the Big Pharma partner. There are no indications of disputes, additional restrictions, or that Lilly retains rights that block the improved CDX. 

Summary of Net Effect

Lilly’s IP primarily facilitates rather than hinders the improved CDX by granting Hemogenyx exclusive rights to necessary collaboration-derived IP, reducing legal risks and enabling continued development/commercialization. It adds defined financial obligations but is not portrayed as a major ongoing limitation. Hemogenyx’s own patents (on sequences, methods, etc.) provide additional layers of protection for the improvements.

Sorry Jezza but forgot to add that yes they are both impressive but for me CBR could be massive if it proceeds as expected.

Yes I saw it Jezza but no mention of Lilly and what it means for the original agreement. Did you read HFH’s post to explain it ? I agree with him.

Also I don’t want to shut anyone up. Stick to facts and we won’t have an issue.

JHFH - my issue with you is that you constantly post your opinion as fact. If you didn’t lie (or deliberately try to deceive) and stuck to facts then we wouldn’t have a problem. I have no issue with positivity but it has to be true not a figment of your imagination or your view through those rose tinted specs again.

I don’t want to be spoon fed and anyone who relies on this board for their due diligence needs to seriously consider their investing strategy.

As for your Avacta comment - another laugh out loud moment. Answer me this - how many raises have they done in the past 12 months and how many have Hemo done. I’m starting to think that Vlad is paying you with the amount of ramping you’re doing here.

Grow up and please start having a more objective stance - your current one is wearing thin.

Jezza - can you direct me to your evidence where the connection is still not in place as I cannot find anything that states this ?

Fair enough Jezza. We’ll agree to disagree 👍

YesI know it was stalled due to financial constraints but what has that got to do with the original posts ?

JHFH - wtf are you on about. Again you’ve stepped into a discussion I was having with Jezza and Kal. HFH confirmed what we had been saying. We have not been informed that any agreement we have with Lilly has been terminated therefore imo it still stands. Also what placing are you talking about ? Please follow the original discussion before making stupid statement - again !

AsmIve said to you previously, if I believe people are making statement I believe to be incorrect I will call them out - is this difficult for you to understand?

Those wear my thought HFH. Lilly still involved. Thanks

Hi Jezza,

Thanks for the update. I’m still sceptical that the Lilly link is dead as we don’t know exactly what enhancements Lonza made and would they be able to still call it CDX if it had completely changed ? Have Lonza just updated the Lilly product. It says CDX has been improved but I don’t think that takes away from the initial Lilly work. Maybe wrong but I guess we’ll find out at some point.

I’ll wait for Jezza to supply the link.

Jezza - if you believe those details to be incorrect, please provide a link to any released information on the subject.

Key Details of the Agreement:

• CDX Licence Agreement (announced around October 2021): Eli Lilly granted Hemogenyx an exclusive worldwide licence to certain intellectual property (IP) that Lilly developed during their prior collaboration on the CDX bispecific antibody (a humanized FLT3/CD3 bispecific for treating acute myeloid leukemia (AML), subsets of acute lymphoblastic leukemia, and conditioning for transplantation). 

• Financial terms: Hemogenyx made an upfront payment of US$250,000 to Lilly. Lilly is eligible for milestone payments of up to US$1 million through Phase II trials, plus additional substantial clinical, regulatory, and commercial milestone payments (tied to minimum sales thresholds), and tiered royalties on future sales. 

Background and Current Status:

• Hemogenyx and Lilly had an earlier collaboration (including a 2020 Biological Investigation and Material Supply Agreement and further development work), during which Lilly contributed to developing and validating CDX. Lilly did not exercise an option to license the IP back, leading to the 2021 licence where rights were effectively transferred to Hemogenyx. 

• The collaboration is described as completed in some documents (with a patent filing for novel sequences following it), but the licence agreement remains active with ongoing potential obligations (milestones and royalties). 

• As of late 2024–early 2026 materials (including Hemogenyx’s investor presentation, pipeline page, and announcements), the company continues to reference CDX as having been “exclusively licensed global rights and developed in collaboration with Eli Lilly.” No public announcements indicate termination of the licence. 

Hemogenyx is advancing its own pipeline (including HG-CT-1 CAR-T therapy), but the CDX licence with Lilly is still in place for that specific asset. For the absolute latest status, check Hemogenyx’s most recent RNS announcements or regulatory filings on their website (hemogenyx.com) or via the London Stock Exchange, as biotech agreements can evolve with development progress.

Correct JHFH

Hi Kal - unfortunately the shares in circulation has doubled since the 2p days and this explains some of the valuation increase.

I have no problem with the raising as £3m is a decent chuck but we’ve heard Vlad say on multiple occasions that II are involved and then they start offloading. He’s also told shareholders to “not worry about the funding as it will be no dilutive” and since those comments with been diluted over 100%. I pray that he hasn’t used previous II this time around.

I think your incorrect Jezza - Hal has explained it below.

Nice post Kal but one or two issues I have :

“ It proves that the big money now views HEMO as a serious clinical contender, not a penny stock.” - we’re currently under 2p old money and are being treated as such.

“By building this war chest now, HEMO isn't just surviving, but they are sprinting.” - don’t think we’re quite at the sprinting mark just yet. Nearly 15 months to treat 3 patients but hopefully things start to improve over the next few months.

Daz - 2 issues with your post :

Manufacturing hardware is established in Estonia and technology transfer with Cellin Technologies will commence imminently. - key word in that sentence is “commence” - when the transfer to Made happened it took months from notification to it actually happening.

“ More good news will drop in shortly, this is only a small dilution, market capital now £45m amazing, Hemo has no debt or big operating costs to keep it afloat” - we’ve given away over 10% of the company in 2 months - for a grand total of £5.5m. That is not a small dilution but it is a small amount.